EU Extends Deadline For Comments On Review Of Tissues And Cells Legislation
Executive Summary
Stakeholders have been given extra time to express their views on whether changes need to be made to the EU legislation on blood, tissues and cells in light of factors such as technological progress and changes in disease transmission risks. A stakeholder event to discuss the issues is to be held in Brussels on Sept. 20.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.